Literature DB >> 15452264

Visualization by live-cell microscopy of disruption of ND10 during herpes simplex virus type 1 infection.

Roger D Everett1, Alexandros Zafiropoulos.   

Abstract

ND10 structures are disrupted during herpes simplex virus type 1 (HSV-1) infection by viral regulatory protein ICP0. The significance of this effect remains controversial, partly because of a report that high-level expression of the major ND10 promyelocytic leukemia (PML) protein precludes ND10 disruption yet does not inhibit HSV-1 infection. Here we demonstrate dramatic reorganization of ND10 during HSV-1 infection by live-cell microscopy, even in the presence of overexpressed PML.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15452264      PMCID： PMC521835          DOI： 10.1128/JVI.78.20.11411-11415.2004

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  29 in total

Review 1.  Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot.

Authors:  D Negorev; G G Maul
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

2.  Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro.

Authors:  Chris Boutell; Seth Sadis; Roger D Everett
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Interactions of herpes simplex virus type 1 with ND10 and recruitment of PML to replication compartments.

Authors:  J Burkham; D M Coen; C B Hwang; S K Weller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Recruitment of herpes simplex virus type 1 transcriptional regulatory protein ICP4 into foci juxtaposed to ND10 in live, infected cells.

Authors:  Roger D Everett; George Sourvinos; Anne Orr
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

5.  Visualization of parental HSV-1 genomes and replication compartments in association with ND10 in live infected cells.

Authors:  George Sourvinos; Roger D Everett
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

Review 6.  The promyelocytic leukemia nuclear body: sites of activity?

Authors:  Christopher H Eskiw; David P Bazett-Jones
Journal:  Biochem Cell Biol       Date:  2002       Impact factor: 3.626

Review 7.  Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies.

Authors:  Katherine L B Borden
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

8.  The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a.

Authors:  Haidong Gu; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-10       Impact factor: 11.205

9.  PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0.

Authors:  Chris Boutell; Anne Orr; Roger D Everett
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Overexpression of promyelocytic leukemia protein precludes the dispersal of ND10 structures and has no effect on accumulation of infectious herpes simplex virus 1 or its proteins.

Authors:  Pascal Lopez; Robert J Jacob; Bernard Roizman
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103
View more
  18 in total

1.  Herpes simplex virus requires poly(ADP-ribose) polymerase activity for efficient replication and induces extracellular signal-related kinase-dependent phosphorylation and ICP0-dependent nuclear localization of tankyrase 1.

Authors:  Zhuan Li; Yohei Yamauchi; Maki Kamakura; Tsugiya Murayama; Fumi Goshima; Hiroshi Kimura; Yukihiro Nishiyama
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Cell fusion-induced activation of interferon-stimulated genes is not required for restriction of a herpes simplex virus VP16/ICP0 mutant in heterokarya formed between permissive and restrictive cells.

Authors:  Meaghan H Hancock; Karen L Mossman; James R Smiley
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

3.  ND10 components relocate to sites associated with herpes simplex virus type 1 nucleoprotein complexes during virus infection.

Authors:  Roger D Everett; Jill Murray
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Regulation of ICP0-null mutant herpes simplex virus type 1 infection by ND10 components ATRX and hDaxx.

Authors:  Vera Lukashchuk; Roger D Everett
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

5.  PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication.

Authors:  Delphine Cuchet; Amanda Sykes; Armel Nicolas; Anne Orr; Jill Murray; Hüseyin Sirma; Joerg Heeren; Alexander Bartelt; Roger D Everett
Journal:  J Cell Sci       Date:  2010-12-20       Impact factor: 5.285

6.  The herpes simplex virus immediate-early ubiquitin ligase ICP0 induces degradation of the ICP0 repressor protein E2FBP1.

Authors:  Yayoi Fukuyo; Nobuo Horikoshi; Alexander M Ishov; Saul J Silverstein; Takuma Nakajima
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

7.  Epigenetic modulation of gene expression from quiescent herpes simplex virus genomes.

Authors:  Michael W Ferenczy; Neal A DeLuca
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

Review 8.  Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing?

Authors:  Christopher D Conrady; Douglas A Drevets; Daniel J J Carr
Journal:  J Neuroimmunol       Date:  2009-10-09       Impact factor: 3.478

9.  A flow cytometric assay for the study of E3 ubiquitin ligase activity.

Authors:  Joshua G Hilliard; Anne L Cooper; Joyce G Slusser; David J Davido
Journal:  Cytometry A       Date:  2009-07       Impact factor: 4.355

10.  Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100.

Authors:  Roger D Everett; Carlos Parada; Philippe Gripon; Hüseyin Sirma; Anne Orr
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.